- Home
- RITR vs SWKH Comparison
RITR vs SWKH Comparison
Compare RITR & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- SWKH
- Stock Information
- Founded
- RITR 2015
- SWKH 1996
- Country
- RITR Hong Kong
- SWKH United States
- Employees
- RITR N/A
- SWKH N/A
- Industry
- RITR
- SWKH Diversified Financial Services
- Sector
- RITR
- SWKH Finance
- Exchange
- RITR NYSE
- SWKH Nasdaq
- Market Cap
- RITR 249.8M
- SWKH 210.8M
- IPO Year
- RITR 2024
- SWKH 1999
- Fundamental
- Price
- RITR $4.60
- SWKH $15.25
- Analyst Decision
- RITR
- SWKH
- Analyst Count
- RITR 0
- SWKH 0
- Target Price
- RITR N/A
- SWKH N/A
- AVG Volume (30 Days)
- RITR 186.8K
- SWKH 8.0K
- Earning Date
- RITR 11-26-2024
- SWKH 11-14-2024
- Dividend Yield
- RITR N/A
- SWKH N/A
- EPS Growth
- RITR N/A
- SWKH N/A
- EPS
- RITR 0.04
- SWKH 0.84
- Revenue
- RITR $32,198,033.00
- SWKH $24,725,000.00
- Revenue This Year
- RITR N/A
- SWKH N/A
- Revenue Next Year
- RITR N/A
- SWKH $6.17
- P/E Ratio
- RITR $108.84
- SWKH $18.07
- Revenue Growth
- RITR 74.80
- SWKH N/A
- 52 Week Low
- RITR $3.30
- SWKH $15.14
- 52 Week High
- RITR $8.75
- SWKH $18.75
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- SWKH 27.72
- Support Level
- RITR N/A
- SWKH $16.17
- Resistance Level
- RITR N/A
- SWKH $17.10
- Average True Range (ATR)
- RITR 0.00
- SWKH 0.53
- MACD
- RITR 0.00
- SWKH -0.15
- Stochastic Oscillator
- RITR 0.00
- SWKH 5.21
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.